Performance Report to Congress for the Animal Generic Drug User Fee Act, FY 2013.

摘要

This report marks the fifth year of FDA performance review under AGDUFA and finalizes performance results for FY 2012, the fourth year of AGDUFA. This report also presents FDAs preliminary accomplishments for FY 2013. It is my pleasure to report that FDA exceeded all performance goals for FY 2012. FDA also exceeded review-time goals for all FY 2012 cohort submissions reviewed or due for review by September 30, 2013. FDA is on track to exceed all performance goals for FY 2013.